Biotech Values

[DewDiligence]

…ENTA…are working on a novel MoA in HBV w the goal of a 3-drug oral cocktail. It’s a long shot but if it works the opportunity is larger than HCV. It’s the kind of opportunity I think a large pharma would take a flier on before final results are in.

Moreover, only ENTA is aiming for an all-oral (no RNAi) functional cure, as far as I know.

ASMB’s 2-DAA attempt at a functional cure (#msg-159327881) was doomed insofar as ABI-70831 was a weak agent, something noted by ENTA’s CEO, Jay Luly, on several occasions.